TRPV2 and urothelial carcinoma: In cancers, the overexpression of TRPV2 was associated with increased survival of patients with hepatocellular carcinoma, glioma and glioblastoma, while the opposite was seen for esophageal squamous cell carcinoma, urothelial carcinoma, prostate, breast and gastric cancer (Santoni et al, 2020).